# Artios Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artios-pharma

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.artios.com
- Total disclosed funding: $502M
- Investors on record: 28

## About

Based in Cambridge, UK, and founded in 2016,  Artios Pharma Limited is a developer of novel cancer treatments designed to target DNA Damage Response (DDR). In November 2025, Artios Pharma Limited raised GBP 87.3 million in series D funding co-led by SV Health Investors, RA Capital Management, with participation from Janus Henderson Investors, IP Group , Sofinnova Partners, Schroders Capital, Piper Heartland Healthcare Capital, Pfizer Venture Investments, Andera Partners, Avidity Partners, EQT Life Sciences, Invus [DUP], M Ventures, Novartis Venture Fund, and Omega Funds. Michael T. Andriole is the current CEO.

The company's medications center on creating treatments through deoxyribonucleic corrosive harm reaction (DDR) pathways to assist changes to their DNA so that it can advance, empowering doctors to specifically slaughter cancer cells through a concept known as manufactured lethality.

The company plans to use the November 2025 funding to advance late-stage trials and progress its DDR ADC program.

## Funding rounds

- Round, Nov 3, 2026, $115M — RA Capital Management, SV Health Investors, Janus Henderson
- Series D, Aug 6, 2025, $114M — Schroders Capital, Sofinnova Partners, Andera Partners, Novartis Venture Fund, EQT Life Sciences, SV Health Investors, Invus [DUP], M Ventures, Omega Funds, Pfizer Venture Investments, RA Capital Management, Janus Henderson Investors, Avidity Partners, Piper Heartland Healthcare Capital, IP Group
- Series C, Jul 26, 2021, $151M — Schroders Capital, Andera Partners, Novartis Venture Fund, EQT Life Sciences, SV Health Investors, Invus [DUP], Longview Innovation, Omega Funds, Piper Sandler, Pfizer Venture Investments, RTW Investments, Arix Bioscience, M Ventures, Soleus Capital, Avidity Partners, CaaS Capital Management, TCG Crossover Management, Deep Track Capital
- Series B, Jul 30, 2018, $85M — Andera Partners, Novartis Venture Fund, EQT Life Sciences, SV Health Investors, Longview Innovation, M Ventures, Pfizer Venture Investments, AbbVie Ventures, Arix Bioscience
- Series A, May 16, 2016, $36M — SV Health Investors, M Ventures, Touchstone Innovations, AbbVie Ventures, Acarix A/S, Sixth Element Capital

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B, Series C, Series D
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A, Series B, Series C, Series D
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A, Series B
- Acarix A/S — Series A
- Sixth Element Capital (https://capitalatlas.ai/funds/sixth-element-capital) — Series A
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B, Series C, Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C, Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C, Series D
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series C, Series D
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B, Series C
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series C, Series D
- Invus [DUP] — Series C, Series D
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series C, Series D
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series C
- Avidity Partners — Series C, Series D
- CaaS Capital Management (https://capitalatlas.ai/funds/caas-capital-management) — Series C
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- Janus Henderson Investors — Series D
- Piper Heartland Healthcare Capital — Series D
- IP Group — Series D
- Janus Henderson (https://capitalatlas.ai/funds/janus-henderson)